4-(2-乙氧基乙氧基)苯胺 | 65999-71-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 4-(2-乙氧基乙氧基)苯胺
• 中文别名: 4-(2-二乙氧基)苯胺1HCl
• 英文名称: 4-(2-ethoxyethoxy)aniline
• CAS: 65999-71-5
• 化学式: C₁₀H₁₅NO₂
• mdl: MFCD03004836
• 分子量: 181.235
• InChiKey: SCFTZBNMULUNNP-UHFFFAOYSA-N

物化性质

• 沸点：
  176 °C(Press: 10 Torr)
• 密度：
  1.056±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  13
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  44.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 海关编码：
  2922299090

反应信息

• 作为反应物：
  描述：

  4-(2-乙氧基乙氧基)苯胺 在 乙醇 作用下， 生成 6-(2-ethoxy-ethoxy)-6'-amino-[2,2']bi[benzo[b]thiophenylidene]-3,3'-dione
  参考文献：
  名称：

  Indigoid vat dyestuffs

  摘要：

  公开号：

  US02080862A1
• 作为产物：
  描述：

  1-n-ethoxy-2-(4-nitrophenoxy)-ethane 在 tin(ll) chloride 作用下， 以 甲醇 为溶剂， 反应 0.5h， 生成 4-(2-乙氧基乙氧基)苯胺
  参考文献：
  名称：

  From EGFR kinase inhibitors to anti-inflammatory drugs: Optimization and biological evaluation of (4-(phenylamino)quinazolinyl)-phenylthiourea derivatives as novel NF-κB inhibitors

  摘要：

  DOI：

  10.1016/j.bioorg.2022.105977

文献信息

• 신규한 헤테로아릴카르복스아마이드 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 포함하는 ＲＡＧＥ 수용체 관련 질환의 예방 또는 치료용 약학적 조성물
  申请人：Seoul National University R&DB Foundation 서울대학교산학협력단(120070509242) Corp. No ▼ 114371-0009224BRN ▼119-82-03684

  公开号：KR101493882B1

  公开（公告）日：2015-02-17

  본 발명은 신규한 헤테로아릴카르복스아마이드 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 포함하는 ＲＡＧＥ 수용체 또는 아세틸콜린에스테라제 활성 관련 질환의 예방 또는 치료용 약학적 조성물에 관한 것이다. 본 발명에 의한 헤테로아릴카르복스아마이드 유도체 화합물은 RAGE 수용체에 길항작용을 함으로써, 신경세포를 손실하는 베타아밀로이드가 RAGE 수용체와 결합하여 뇌 내로 이동하는 것을 억제하며, 이로 인한 베타아밀로이드의 과다축적으로 형성되는 플라크 생성을 억제 효과가 우수하다. 또한, 기억 기능에 있어서 중요한 화학물질인 아세틸콜린을 분해하는 아세틸콜린에스테라제를 저해하는 효과가 뛰어나므로, RAGE 수용체 또는 아세틸콜린에스테라제 활성 관련 질환인 알츠하이머 질환, 뇌혈관성 치매증, 두부 손상에 의한 치매, 다경색 치매, 알츠하이머 질환과 다경색 치매의 혼합형 또는 알코올성 치매 등을 포함하는 치매, 픽(pick)병, 크루츠-야콥(Creutzfeldt-jakob)병, 저갑상선증, 두부손상에 의한 파킨슨(Parkinson)병, 헌팅턴(Huntington)병 등의 예방 또는 치료에 유용하게 사용될 수 있다.

  This is the Chinese translation of the text you provided: 该发明涉及新型的杂环芳基羰胺衍生物或其药学上可接受的盐、其制备方法以及包含它的ＲＡＧＥ受体或乙酰胆碱酯酶活性相关疾病的预防或治疗药学组合物。根据本发明的杂环芳基羰胺衍生物化合物通过对RAGE受体的拮抗作用，抑制与RAGE受体结合并进入大脑的β-淀粉样蛋白导致神经细胞丧失，从而优越地抑制由此导致的β-淀粉样蛋白过度积累形成斑块的效果。此外，由于其出色的抑制分解乙酰胆碱这一对记忆功能至关重要的化学物质的乙酰胆碱酯酶的作用，因此，RAGE受体或乙酰胆碱酯酶活性相关疾病如阿尔茨海默病、脑血管性痴呆症、脑损伤所致痴呆、多发性硬化症痴呆、阿尔茨海默病和多发性硬化症痴呆的混合型或酒精性痴呆等包括痴呆、皮克病、克罗伊茨-雅各布病、甲状腺功能减退症、脑损伤所致帕金森病、亨廷顿病等的预防或治疗可以得到有效应用。
• Heterocyclic compounds as ligands of the GABAA receptor
  申请人：——

  公开号：US20030105081A1

  公开（公告）日：2003-06-05

  Disclosed are heterocyclic compounds of the formula 1 and the pharmaceutically acceptable salts thereof wherein the variables A, V, Y, J, E, X, T, G, Q, W, Z, b, n and m are defined herein. These compounds are highly selective agonists, antagonists or inverse agonists for GABA A brain receptors or prodrugs of agonists, antagonists or inverse agonists for GABA A brain receptor.

  揭示了具有以下公式的杂环化合物及其药用可接受的盐，其中变量A、V、Y、J、E、X、T、G、Q、W、Z、b、n和m在此处被定义。这些化合物是GABA A 脑受体的高度选择性激动剂、拮抗剂或逆激动剂，或者是GABA A 脑受体的激动剂、拮抗剂或逆激动剂的前药。
• INHIBITORS OF BRUTON'S TYROSINE KINASE
  申请人：Pharmacyclics, Inc.

  公开号：US20150158865A1

  公开（公告）日：2015-06-11

  Disclosed herein are reversible and irreversible inhibitors of Bruton's tyrosine kinase (Btk). Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are described, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

  本文披露了布鲁顿酪氨酸激酶（Btk）的可逆和不可逆抑制剂。还披露了包括这些化合物的药物组合物。描述了使用Btk抑制剂的方法，单独或与其他治疗剂联合用于治疗自身免疫疾病或症状、异种免疫疾病或症状、包括淋巴瘤在内的癌症，以及炎症性疾病或症状。
• Substituted fused pyrroleoximes and fused pyrazoleoximes
  申请人：——

  公开号：US20020128236A1

  公开（公告）日：2002-09-12

  Disclosed are compounds of the formula 1 and the pharmaceutically acceptable salts thereof wherein R, Ar, A, n, R 1 and R 2 are defined herein. These compounds are highly selective agonists, antagonists or inverse agonists for GABA A brain receptors or prodrugs of agonists, antagonists or inverse agonists for GABA A brain receptors and are therefore useful in the diagnosis and treatment of anxiety, depression, Down Syndrome, sleep and seizure disorders, overdose with benzodiazepine drugs and for enhancement of memory. Pharmaceutical compositions, including packaged pharmaceutical compositions, are also disclosed.

  揭示了公式1的化合物及其药学上可接受的盐，其中R、Ar、A、n、R1和R2在此处定义。这些化合物是高度选择性的GABAA脑受体的激动剂、拮抗剂或逆拮抗剂，或者是GABAA脑受体的激动剂、拮抗剂或逆拮抗剂的前药，因此在焦虑、抑郁、唐氏综合症、睡眠和癫痫障碍、苯二氮卓类药物过量和增强记忆的诊断和治疗中非常有用。还披露了包括包装的药物组合物在内的药物组合物。
• 1,3,3-Trimethyl-2-methylene indoline cationic n-methyl azo dyes
  申请人：Ciba-Geigy Corporation

  公开号：US04168264A1

  公开（公告）日：1979-09-18

  New yellow cationic dyes of the formula ##STR1## ARE DISCLOSED WHEREIN X represents hydrogen or halogen, R represents an optionally substituted alkyl group or cycloalkyl group, Or --CH.sub.2 -- if this is linked with the phenylene group in the o-position with respect to the oxygen bond to form a 6-membered ring and n represents 1, R.sub.1 represents an unsubstituted, straight-chain or branched-chain alkyl group having 1 to 5 carbon atoms, R.sub.2 represents a substituted, or preferably unsubstituted, straight-chain or branched-chain alkyl group having 1 to 5 carbon atoms, N represents the numbers 1 or 2, and An represents an anion, which dyes are useful for dyeing and printing of textile material especially polyacrylonitrile.

  公开了一种新的黄色阳离子染料的化学式，其中X代表氢或卤素，R代表可选取代的烷基或环烷基，或者--CH.sub.2--如果这与苯基在氧原子键的邻位相连形成一个6元环，n代表1，R.sub.1代表未取代的直链或支链烷基，其碳原子数为1至5，R.sub.2代表取代或更好地未取代的直链或支链烷基，其碳原子数为1至5，N代表数字1或2，An代表一个阴离子。这些染料适用于染色和印刷纺织材料，特别是聚丙烯腈。